Four patients with proliferative glomerulonephritis due to systemic lupus erythematosus were treated with intravenous methyl prednisolone 'pulse' therapy. In all, eight courses of therapy were given, three for acute oliguric renal failure; and on each occasion there was a good response to the treatment. Clinical, histological and immunological details of the patients are presented. The diagnosis, treatment, and monitoring of disease activity in lupus nephritis are discussed in the light of this experience.
Introduction
Renal involvement in systemic lupus erythematosus (SLE) has been studied extensively and death from frenal failure is one of the serious consequences of the disease (Dubois and Tuffanelli, 1964; Estes and Christian, 1971; Feng, Cheah and Lee, 1973) . Renal histopathological changes are valuable both as a prognostic indicator and in monitoring disease activity. The prognosis is broadly proportional to the extent of glomerular proliferative changes and acute renal failure due to diffuse proliferative glomerulonephritis with crescent formation is almost invariably associated with early death (Baldwin et al., 1970; Pollack, Pirani and Kark, 1961; Baldwin and Gallo, 1975) .
Whilst oral corticosteroids alone are of some benefit in the treatment of diffuse proliferative lupus nephritis (LN) (Pollack et al., 1961 (Pollack et al., , 1973 Ackerman, 1970) other forms of therapy have recently been advocated, especially for patients with severe renal failure. Some success has been reported with combination therapy consisting of steroids, immunosuppressants, dipyridamole and anticoagulants, but morbidity and mortality attributable to therapy do occur (Ponticelli et al., 1974; Brown et ). By June 1976 her creatinine clearance had declined in 9 months from 50 to 30 ml/min and she had developed leucopenia and thrombocytopenia. The ANF was now positive and the anti-DNA antibody was raised. Following methyl prednisolone one g i.v. daily for 5 days the white cell and platlet counts and anti-DNA antibody were normal and the creatinine clearance had risen to 50 ml/min. A further course of methyl prednisolone was given in October 1976 when her creatinine clearance fell abruptly to 10 ml/min. The anti-DNA antibody and serum complement levels were normal. The creatinine clearance rose following the course to 48 ml/min. 
Case 4
A 57-year-old man presented in August 1976 with oligo-anuric renal failure, oedema and hypertension. The antinuclear factor was negative but anti-DNA antibody raised and CH50, Clq and C3 low. There were red cells and granular casts in the urine. Renal biopsy showed diffuse proliferative glomerulonephritis with crescents. Oliguria persisted despite oral steroids and azathioprine so he received a 5-day course of methyl prednisolone followed by low dose oral steroids and azathioprine (Fig. 2) . Renal function improved, serum complement levels returned to normal and urinary sediment cleared. A further course of methyl prednisolone was given in September 1976 when renal function declined and urinary cell and cast excretion recurred. Recovery was again observed. A renal biopsy showed less cellularity with progression towards sclerosis. Crescents were still present.
Discussion
The diagnosis of SLE is often difficult at initial presentation. Cohen and Canoso (1972) found that only 67% of their patients fulfilled the American Rheumatism Association (ARA) criteria (Cohen, Reynolds and Frankin, 1971) Mallick, unpublished).
The criteria for diagnosing systemic lupus erythematosus are becoming more precise but difficulties still arise (Davis et al., 1973) . Serum complement and anti-DNA antibody levels are affected in systemic lupus erythematosus and their value as markers of disease activity has been extensively reviewed (Schur and Sanderson, 1968; Epstein, 1973; Schur, 1975; Hughes, 1975; Bardana et al., 1975; Cameron et al., 1976) . The LE cell phenomenon is a less sensitive index of the presence or activity of its eponym than was previously supposed (Sharp et al., 1971) .
The varying natural history of SLE makes assessment of therapy difficult; particularly in cases with only mild renal involvement where prolonged survival is usual (Baldwin et al., 1970; Zweiman et al., 1968) but is easier to judge in patients with severe diffuse proliferative lesions. In such cases treatment with corticosteroids in a dose of 40-60 mg/day over prolonged periods has improved survival significantly but steroid toxicity is frequent (Feng et al., 1973; Pollack et al., 1961 Pollack et al., , 1973 . Indeed, it contributes to early mortality and may be responsible for some of the late morbidity and mortality of lupus patients (Bulkley and Roberts, 1975; Urowitz et al., 1976) . Gary, Maher and Schreiner (1967) found that intensive therapy sufficient to suppress disease activity during the acute phase may be safely followed by minimal daily steroid therapy. Cathcart et al. (1976) showed that methyl prednisolone pulse therapy results in rapid improvement in renal function and reversal of associated immunological abnormalities, and that these benefits are sustained with low dose maintenance steroid therapy. Recent evidence suggests that methyl prednisolone therapy reduces the level of circulating soluble immune complexes in patients with lupus nephritis even when large doses of oral prednisolone fail to do so, and that this fall correlates well with improvement in clinical activity of the disease (Levinsky, Cameron and Soothill, 1977) .
The clinical presentation and type of renal involvement in the present patients suggested a poor prognosis, since two of them were originally in acute oliguric renal failure and, in all, the biopsy appearances were of severe diffuse proliferative lupus nephritis with glomerular crescent formation. Case 1 (initially thought to have idiopathic glomerular disease) is possibly unique in having suffered and survived four episodes of oliguric renal failure due to lupus nephritis. Therapy with oral prednisolone produced benefit but at a price. She developed so grotesque an appearance (florid Cushingoid habitus with extensive striae) that she was rejected by her husband and family. Later episodes were successfully treated with methyl prednisolone pulses combined with maintenance low dose oral prednisolone and there were no significant side effects. In Case 4, who was initially anuric, methyl prednisolone pulse therapy produced a dramatic improvement in renal function and a subsequent relapse was rapidly reversed by a further pulse.
Despite improvement in the glomerular filtration rate following methyl prednisolone only a transient reduction in proteinuria was observed in the four patients but, as noted previously, the level of proteinuria is a poor guide to renal disease activity (Pollack et al., 1961; Ackerman, 1970) .
The effect of methyl prednisolone pulse therapy on the immunological abnormalities associated with lupus nephritis was impressive. In Case 3, serum complement levels, which had remained low during several months of oral steroid therapy were, with the exception of C4, normal within a few weeks of starting pulse therapy. A similar response was obtained in all the patients with evidence of complement consumption. In all cases, there was a sharp fall in anti-DNA antibody titres with therapy.
In Case 4, despite clinical and immunological improvement a repeat renal biopsy two weeks after the second pulse showed only slight decrease in cellularity and progression towards sclerosis. The findings on immunofluorescence remained unchanged and on electron microscopy there was still extensive immune complex deposition in mesangial and intramembranous locations. It seems likely that factors other than the simple presence of immune complexes play an important part in the renal damage of lupus nephritis and are altered by methyl prednisolone therapy.
Extrarenal manifestations of disease were suppressed in the present patients even when this had not been achieved by oral steroids. No side effects associated with methyl prednisolone therapy were observed and because of the lower maintenance steroid dosage, Cushingoid features subsequently regressed in two of the patients. Methyl prednisolone pulse therapy is effective in the treatment of severe proliferative lupus nephritis regardless of the degree of renal impairment and should be considered as the first line of treatment for this condition. Response to such therapy appears to be rapid and, because of its simplicity and lack of side effects, it can be readily repeated if relapse occurs. In the authors' experience, once remission has been achieved it can be maintained with low dose daily or alternate day maintenance steroid therapy which produces few side effects.
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